Mark Denison

Vials with medication and syringe on blue methacrylate table. Horizontal composition. Top elevated view.

VUMC studies provide key positive results for COVID-19 vaccine in early-stage clinical trial

An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.

New study supports remdesivir as COVID-19 treatment

This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.

Attendees take part in last week’s online Medical Scientist Training Program seminar.

Medical Scientist Training Program adapts to COVID-19 challenges

The Medical Scientist Training Program has been intentional in approaching the challenges presented by COVID-19.

VUMC team aids development of potential antiviral drug for COVID-19

Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.

Denison named director of Pediatric Infectious Diseases

Mark Denison, MD, has been named director of the Division of Pediatric Infectious Diseases in the Vanderbilt Department of Pediatrics.

Team investigates antiviral that inhibits SARS, MERS

A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science Translational Medicine.

1 2 3